HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Navarro, S. Articles by España, F. Search for Related Content PubMed PubMed Citation Articles by Navarro, S. Articles by España, F. Related Collections Related Article

Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation

¹ Research Center and
² Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain;
³ Hemostasis and Thrombosis Research Center, Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Correspondence: Francisco España, Hospital Universitario La Fe, Centro de Investigación, Av. Campanar 21, 46009 Valencia, Spain. E-mail:espanya_fra{at}gva.es

Background: Haplotypes A1 and A3 in the endothelial protein C receptor (EPCR) gene are tagged by 4678G/C and 4600A/G respectively. We assessed whether these haplotypes modify the risk of venous thromboembolism in carriers of the prothrombin 20210A allele.

Design and Methods: We genotyped 4678G/C and 4600A/G in 246 20210A carriers: 84 venous thromboembolism propositi and 162 relatives (13 symptomatic), and in 140 relatives not carrying the 20210A variant. Prothrombin and soluble EPCR (sEPCR) levels were also measured.

Results: Among propositi, the mean age at first onset was lower in carriers (35±8 years) than non-carriers of the 4600G allele (44±14 years) (p=0.004). The probability of being free of thrombosis at age 40 was lower in 20210A carriers with the EPCR 4600G allele (p=0.015). The frequency of the 4600G allele (p=0.002) and the levels of prothrombin antigen (p=0.002) and sEPCR (p<0.001) were higher in the propositi than in their asymptomatic relatives. Multivariate analyses showed that the presence of the 4600G allele (OR=2.5, 95% confidence interval 1.3–5.0), sEPCR >147 ng/mL (2.8, 1.5–5.2) and prothrombin >129% (3.8, 1.8–8.3) all increased the thrombotic risk. In bivariate analysis, including the 4600G allele and sEPCR>147 ng/mL, only the latter remained associated with risk.

Conclusions: These results show that in 20210A carriers the venous thromboembolism risk is influenced both by the actual prothrombin levels and by the EPCR A3 haplotype, via its effect on sEPCR levels.

Key words: endothelial protein C receptor, prothrombin G20210A mutation, venous thromboembolism, prothrombin level, activated protein C.

Related Article

Endothelial cell protein C receptor and the risk of venous thrombosis

Sophie Gandrille
Haematologica 2008 93: 812-816. [Full Text] [PDF]

This article has been cited by other articles:

				S. Gandrille Endothelial cell protein C receptor and the risk of venous thrombosis Haematologica, June 1, 2008; 93(6): 812 - 816. [Full Text] [PDF]